Comparison of the biodistribution of two hypoxia markers [ 18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 31, Issue 4, 2004, Pages 513-520

  Grönroos, Tove ^a   Bentzen, Lise ^b   Marjamäki, Päivi ^a   Murata, Rumi ^b   Horsman, Michael R ^b   Keiding, Susanne ^b   Eskola, Olli ^a   Haaparanta, Merja ^a   Minn, Heikki ^a   Solin, Olor ^a  

^a TURKU PET CENTRE   (Finland)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Digital autoradiography; Hypoxia; Murine tumours; 18F Fluoroerythronitroimidazole; 18F Fluoromisonimidazole

Indexed keywords

CARBOGEN; FLUORINE 18; FLUOROERYTHRONITROIMIDAZOLE F 18; FLUOROMISONIMIDAZOLE F 18; IMIDAZOLE DERIVATIVE; NITROIMIDAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BLOOD; BREAST CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; HEART; HUMAN; HYPOXIA; KIDNEY; LIVER; LUNG; MOUSE; MUSCLE; NECROSIS; NONHUMAN; OXYGENATION; RADIOACTIVITY; RADIOISOTOPE DISTRIBUTION; STATISTICAL SIGNIFICANCE; TISSUE DISTRIBUTION; TISSUE SECTION; TUMOR; TUMOR VOLUME;

EID: 11144357375     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1404-x     Document Type: Article

References (40)

1. Moulder JE, Rockwell S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 1984; 10:695-712.
2. Overgaard J, Horsman MR. Modification of hypoxia induced radioresistance in tumours by the use of oxygen and sensitizers. Semin Radiat Oncol 1996; 6:10-21.
3. Chaplin DJ, Horsman MR, Trotter MJ, Siemann DW. Therapeutic significance of microenvironmental factors. In: Molls M, Vaupel P, eds. Medical radiobiology: blood perfusion and microenvironment of human tumours. Heidelberg Berlin New York: Springer; 1998:133-143.
4. Höckel M, Schlenger K, Aral B, Mitze M, Schäffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56:4509-4515.
5. Nordsmark M, Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 2000; 57:39-43.
6. Horsman M. Measurement of tumor oxygenation. Int J Radiat Oncol Biol Phys 1998; 42:701-704.
7. Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 1998; 46:229-237.
8. Varghese AJ, Gulyas S, Mohindra JK. Hypoxia-dependent reduction of 1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol by Chinese hamster ovary cells and KHT tumor cells in vitro and in vivo. Cancer Res 1976; 36:3761-3765.
9. Chapman JD. Hypoxic sensitizers - implications for radiation therapy. N Engl J Med 1979; 301:1429-1432.
10. Chapman JD, Franko AJ, Sharplin J. A marker for hypoxic cells in tumours with potential clinical applicability. Br J Cancer 1981; 43:546-550.
11. 14C-misonidazole to hypoxic cells in V79 spheroids. Br J Cancer 1982; 45:694-699.
12. Raleigh JA, Franko AJ, Koch CJ, Born JL. Binding of misonidazole to hypoxic cells in monolayer and spheroid culture: evidence that a side-chain label is bound as efficiently as a ring label. Br J Cancer 1985; 51:229-235.
13. Rasey J, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA. Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiation Oncology Biol Phys 1989; 17:985-991.
14. Kubota K, Tada M, Yamada S, Hori K, Saito S, Iwata R, Sato K, Fukuda H, Ido T. Comparison of the distribution of fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumour tissue. Eur J Nucl Med 1999; 26:750-757.
15. Rasey J, Casciari JJ, Hofstrand PD, Muzi M, Graham MM, Chin LK. Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole. Radiat Res 2000; 153:84-92.
16. 18F]fluoro-2-deoxyglucose. Acta Oncol 2000; 39:629-637.
17. 18F] fluoromisonidazole (FMISO). Nucl Med Biol 2002; 29:191-197.
18. 2 electrode measurements: influence of tumour volume and carbogen breathing. Acta Oncol 2002; 41:304-312.
19. Koh WJ, Rasey JS, Evans ML, Grierson JR, Lewellen TK, Graham MM, Krohn KA, Griffin TW. Imaging of hypoxia in human tumors with [F-18] fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992; 22:199-212.
20. Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 1992; 33:2133-2137.
21. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996; 36:417-428.
22. Yeh SH, Liu RS, Wu LC, Yang DJ, Yen SH, Chang CW, Yu TW, Chou KL, Chen KY. Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma. Eur J Nucl Med 1996; 23:1378-1383.
23. 18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 2003; 30:695-704.
24. 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiother Oncol 2003; 67:339-344.
25. Yang DJ, Wallace S, Cherif A, Chun L, Gretzer MB, Kim EE, Podoloff DA. Development of F-18-labeled fluoroerythromtroimidazole as a PET agent for imaging tumor hypoxia. Radiology 1995; 194:795-800.
26. Chung JK, Chang YS, Lee YJ, Kim YJ, Jeong JM, Lee DS, Jang JJ, Lee MC. The effect of tumor size on F-18-labeled fluorodeoxyglucose and fluoroerythronitroimidazole uptake in a murine sarcoma model. Ann Nucl Med 1999; 13:303-308.
27. 18F]FETNIM: a potential hypoxia marker for PET. J Nucl Med 2001; 42:1397-1404.
28. 18F]fluoroerythronitroimidazole PET. J Nucl Med 2001; 42:1643-1652.
29. 18F]FETNIM) and PET using tumor-to-plasma ratio. Eur J Nucl Med Mol Imaging 2003; 30:101-108.
30. Overgaard J. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. Int J Radiat Oncol Biol Phys 1980; 6:1507-1517.
31. Horsman MR, Khalil AA, Siemann DW, Grau C, Hill SA, Lynch EM, Chaplin DJ, Overgaard J. Relationship between radiobiological hypoxia in tumors and electrode measurements of tumor oxygenation. Int J Radiat Oncol Biol Phys 1994; 29:439-442.
32. Olive PL, Horsman MR, Grau C, Overgaard J. Detection of hypoxic cells in a C3H mouse mammary carcinoma using the comet assay. Br J Cancer 1997; 76:694-699.
33. 18F]fluoromisonimidazole. Appl Radiat Isot 1993; 44:1085-1091.
34. Grau C, Horsman MR, Overgaard J. Influence of carboxyhemoglobin level on tumor growth, blood flow, and radiation response in an experimental model. Int J Radiat Oncol Biol Phys 1992; 22:421-424.
35. Horsman MR, Siemann DW, Nordsmark M, Khalil AA, Overgaard J, Chaplin DJ. The combination of nicotinamide and carbogen breathing to improve tumour oxygenation prior to radiation treatment. In: Hogan MC, Mathieu-Costello O, Poole DC, Wagner PD, eds. Oxygen transport to tissue XVI. New York: Plenum; 1994:635-642.
36. 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999; 40:177-183.
37. Horsman MR, Khalil AA, Nordsmark M, Grau C, Overgaard J. Relationship between radiobiological hypoxia and direct estimates of tumour oxygenation in a mouse tumour model. Radiother Oncol 1993; 28:69-71.
38. Nordsmark M, Grau C, Horsman MR, Jorgensen HS, Overgaard J. Relationship between tumour oxygenation, bioenergetic status and radiobiological hypoxia in an experimental model. Acta Oncol 1995; 34:329-334.
39. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989; 49:6449-6465.
40. Khalil AA, Horsman MR, Overgaard J. The importance of determining necrotic fraction when studying the effect of tumour volume on tissue oxygenation. Acta Oncol 1995; 34:297-300.